Merck & Co buys in oral GLP-1 RA from China’s Hansoh
US pharma giant Merck & Co (NYSE: MRK) and Chinese biopharma Hansoh Pharma (03692.HK) have entered into an exclusive global license agreement for HS-10535, an investigational pre-clinical oral small molecule GLP-1 receptor agonist (RA).
Merck joins the likes of Amgen (Nasdaq: AMGN), Pfizer (NYSE: PFE), AstraZeneca (LSE: AZN), Structure Therapeutics and Viking Therapeutics (Nasdaq: VKTX) among companies testing oral drugs for obesity in the hope they will provide patients a more convenient option than injectable options.
Under the agreement, Hansoh has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535 and will receive an upfront payment of $112 million. The company is also eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze